KEDRION BIOPHARMA Trademark

Trademark Overview


On Monday, February 10, 2025, a trademark application was filed for KEDRION BIOPHARMA with the United States Patent and Trademark Office. The USPTO has given the KEDRION BIOPHARMA trademark a serial number of 79428966. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, April 14, 2026. This trademark is owned by KEDRION S.p.A.. The KEDRION BIOPHARMA trademark is filed in the Pharmaceutical Products, Advertising, Business and Retail Services, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Scientific and technological services, namely, research, analysis, and testing, in the field of pharmaceuticals, medical disorders and the treatment of medical disorders, and clinical trials, ; medical and pharmacological research services; providing information and data in relation to medical research and development in the field of pharmaceuticals and clinical trials; providing scientific research information in the field of medical disorders and their treatment; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical research; biological research, clinical research and medical research in the field of pharmaceuticals and clinical trials; design and development of computer software for use with medical technology; scientific research on the subject of pharmaceuticals; providing information technology services for the pharmaceutical and healthcare industries; providing information about the results of clinical trials for pharm...

Medical services and small molecule therapy services; medical consultancy in relation to medical and pharmaceutical field; health center services for therapeutical purposes

Pharmaceutical products for the treatment of primary and secondary immunodeficiency disorders, coagulation disorders, autoimmune diseases treatable with immunoglobulins, and other conditions treatable with plasma derived therapies, biologic therapies, and small molecules therapies; Pharmaceutical preparations for the treatment of primary and secondary immunodeficiency disorders, coagulation disorders, autoimmune diseases treatable with immunoglobulins, and other conditions treatable with plasma derived therapies, biologic therapies, and small molecules therapies

Business management; business administration; office functions in the nature of regulatory documentation management for biopharmaceutical activities and pharmaceutical regulatory compliance for others; Business administration in the nature of sales administration
kedrion biopharma

General Information


Serial Number79428966
Word MarkKEDRION BIOPHARMA
Filing DateMonday, February 10, 2025
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, April 14, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, April 14, 2026

Trademark Statements


NOT AVAILABLE"BIOPHARMA"
Goods and ServicesScientific and technological services, namely, research, analysis, and testing, in the field of pharmaceuticals, medical disorders and the treatment of medical disorders, and clinical trials, ; medical and pharmacological research services; providing information and data in relation to medical research and development in the field of pharmaceuticals and clinical trials; providing scientific research information in the field of medical disorders and their treatment; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical research; biological research, clinical research and medical research in the field of pharmaceuticals and clinical trials; design and development of computer software for use with medical technology; scientific research on the subject of pharmaceuticals; providing information technology services for the pharmaceutical and healthcare industries; providing information about the results of clinical trials for pharmaceutical products
Goods and ServicesMedical services and small molecule therapy services; medical consultancy in relation to medical and pharmaceutical field; health center services for therapeutical purposes
Description of MarkThe mark consists of the wording "KEDRION" having the letter "K" formed partially by a liquid shaped stylization above the wording "BIOPHARMA".
Goods and ServicesPharmaceutical products for the treatment of primary and secondary immunodeficiency disorders, coagulation disorders, autoimmune diseases treatable with immunoglobulins, and other conditions treatable with plasma derived therapies, biologic therapies, and small molecules therapies; Pharmaceutical preparations for the treatment of primary and secondary immunodeficiency disorders, coagulation disorders, autoimmune diseases treatable with immunoglobulins, and other conditions treatable with plasma derived therapies, biologic therapies, and small molecules therapies
Goods and ServicesBusiness management; business administration; office functions in the nature of regulatory documentation management for biopharmaceutical activities and pharmaceutical regulatory compliance for others; Business administration in the nature of sales administration

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, July 31, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class035 - Advertising; business management; business administration; office functions.
US Class Codes100, 101, 102
Class Status Code6 - Active
Class Status DateThursday, July 31, 2025
Primary Code035
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, July 31, 2025
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, July 31, 2025
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameKEDRION S.p.A.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressIT

Party NameKEDRION S.p.A.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressIT

Trademark Events


Event DateEvent Description
Thursday, July 31, 2025SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, August 1, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, August 1, 2025APPLICATION FILING RECEIPT MAILED
Saturday, August 2, 2025ASSIGNED TO EXAMINER
Monday, August 11, 2025NON-FINAL ACTION WRITTEN
Tuesday, August 12, 2025NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, September 24, 2025REFUSAL PROCESSED BY MPU
Wednesday, September 24, 2025NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, October 10, 2025REFUSAL PROCESSED BY IB
Wednesday, March 18, 2026TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 18, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 18, 2026TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, March 18, 2026APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 8, 2026NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 14, 2026PUBLISHED FOR OPPOSITION
Tuesday, April 14, 2026OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED